Correction: Oliveira et al. Discovery of a Necroptosis Inhibitor Improving Dopaminergic Neuronal Loss after MPTP Exposure in Mice. Int. J. Mol. Sci. 2021, 22, 5289

In the original publication [1], there was a mistake in Figure 3 as published. In Figure 3, panel A, representative images of tyrosine hydroxylase-positive immunostaining in substantia nigra from MPTP-injected mice treated with Nec-1s and Oxa-12 were wrongly selected in the original manuscript. The corrected Figure 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Figure

Figure 3. Oxa12 protects from MPTP-driven dopaminergic neuronal loss. Representative images of TH-positive immunostaining from control- and MPTP-injected mice treated with vehicle, Nec-1s or Oxa12 in the SN (A) and the striatum (B), and respective quantification. Scale bar, 100 µm. * p [less than] 0.05 vs. control mice.

Reference

1. Oliveira, S.R.; Dionísio, P.A.; Gaspar, M.M.; Ferreira, M.B.T.; Rodrigues, C.A.B.; Pereira, R.G.; Estevão, M.S.; Perry, M.J.; Moreira, R.; Afonso, C.A.M. et al. Discovery of a Necroptosis Inhibitor Improving Dopaminergic Neuronal Loss after MPTP Exposure in Mice. Int. J. Mol. Sci.; 2021; 22, 5289. [DOI: https://dx.doi.org/10.3390/ijms22105289] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34069782]